Novavax Collaborates with Commonwealth of Australia to Supply 40M doses of NVX-CoV2373 for COVID-19
Shots:
- Novavax has signed a non-binding Heads of Terms document with the Australian Government to supply 40M doses of NVX-CoV2373 for the Australian community
- The delivery will start as early as H1’21- following the completion of P-III study and the TGA’s approval of the vaccine. The vaccine regimen is expected to require two doses per individual- administered 21 days apart.
- NVX-CoV2373 is evaluated in P-ll trial in the UK and 2 ongoing P-ll studies that began in Aug’2020- a P-llb trial in SA- and a P-l/ll continuation in the US and Australia. Additionally- Novavax has multiple agreements for the supply of NVX-CoV2373 directly to the US- UK- Canada- and through partnerships- supply to Japan- South Korea- and India
Ref: GlobeNewswire | Image: MediCircle
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com